INTRODUCTION {#s1}
============

Infection with a human papillomavirus with a high-risk genotype (hrHPV) is the only known etiologic risk factor for the development of cervical cancer and a necessary step in carcinogenesis \[[@R1]--[@R4]\]. The development of cervical cancer is strongly associated with previous infection with hrHPV, and cervical cancer represents 53.4% of all hrHPV-associated cancers in women \[[@R5]\]. Direct referral of HPV16/18-positive women for colposcopy by primary hrHPV screening is a clinical practice in the USA and will be standard clinical practice in both Australia and New Zealand soon; other countries adopting primary HPV screening in the future will likely also adopt this partial genotyping protocol \[[@R6]--[@R9]\].

The American Cancer Society (ACS) and the American Society for Colposcopy and Cervical Pathology (ASCCP) recommend that either co-testing every 5 years or cytology-only screening every 3 years should be implemented for women aged 30--65 years, whereas cytology alone should be performed for women between 21 and 30 years of age \[[@R9]\]. Several studies have shown that primary screening for hrHPV is more sensitive than cytology; however, it is less specific, and the resulting decreased positive predictive value (PPV) for CIN3 may lead to over-referral and overtreatment of patients \[[@R10]--[@R12]\]. Therefore, women with specimens testing positive for hrHPV require additional triage. An approach that has gradually gained favor for women aged over 25 or 30 years is the use of high-sensitivity hrHPV testing as the primary screening method, followed by triage of hrHPV-positive women by high-specificity Pap smear. In early 2015, the Society of Gynecologic Oncology and the ASCCP jointly issued interim clinical guidance regarding the use of primary testing for high-risk human papillomavirus for cervical cancer screening. The interim clinical guidance provides for the use of primary screening for hrHPV as a possible method for early cervical pre-cancer and cancer detection in the United States, based on academic guidance. The interim clinical guidance increases the number of cervical cancer programs in the United States from two to three \[[@R13],[@R14]\].

In China, cervical cancer remains the seventh-leading cause of death from cancer among females, and there were almost 62,000 new cases and 30,000 deaths due to cervical cancer in 2012 \[[@R15]\]. In urban areas of China, cervical cancer diagnosis procedures are well established; however, awareness of cervical cancer screening is still deficient. In certain developed cities, such as Beijing and Shanghai, the incidence of cervical cancer has decreased significantly owing to the wide promotion of cervical cancer prevention information and opportunistic screening in hospitals. In a study of 37 cities in China, the total positive rate for hrHPV was 21.07%, ranging from 18.42% to 31.94% and varying by region \[[@R16]\]. From HPV genotyping studies, the most common HPV genotypes in Chinese women with cervical cancer are HPV-16, -18, -58, -33, and -52 \[[@R2]\]. It is difficult to achieve co-testing (i.e., HPV testing combined with cytology screening) or cytology testing as the primary screening method in China in the short term because of the lack of infrastructure to support such a screening program across the huge Chinese population.

The use of HPV testing has increased dramatically in China in recent years because of the achievement of consistent and repeatable results. The lack of clinical validation of the majority of HPV tests used in hospitals has led to confusion and huge numbers of women undergoing colposcopic examination. The aims of cervical cancer screening are to discover high-grade lesions or cancer, rather than to detect the virus, whose presence does not necessarily indicate malignant disease and can thus lead to unnecessary anxiety for the women tested. Therefore, there is an urgent need for an objective, reproducible, and accurate method of screening for cervical cancer in China.

One such screening possibility arises from the field of epigenetics \[[@R17]\]. Numerous investigations have reported that gene-specific hypermethylation, which occurs in the pre-invasive and invasive phases of cervical cancer, is a promising biomarker for early diagnosis \[[@R18],[@R19]\]. Several studies examining the genes paired box 1 (*PAX1*), sex determining region Y-box 1 (*SOX1*), zinc finger protein 582 (*ZNF582*), and NK6 transcription factor-related locus1 (*NKX6-1*) have reported their potential as biomarkers for cervical cancer screening and for triage of cytological diagnoses and high-risk HPV infection groups \[[@R20]--[@R25]\]. In fact, methylated *PAX1* (*PAX1*^*m*^), *SOX1* (*SOX1*^*m*^), *ZNF582* (*ZNF582*^*m*^), and *NKX6-1* (*NKX6-1*^*m*^) have been extensively documented as highly sensitive biomarkers for detection of cervical intraepithelial neoplasia at grade 3 or higher (CIN3+) \[[@R26]\]. In particular, *ZNF582*^*m*^ has been found to have clinical potential for cancer detection. Clinically, *ZNF582*^*m*^ demonstrated 70% sensitivity and 82% specificity for CIN3+ lesions in a Taiwanese case-control cohort \[[@R27]\]. *ZNF582*^*m*^ also has good sensitivity and specificity for triage of low-grade squamous intraepithelial lesion (LSIL), with values of 73% and 71%, respectively \[[@R22]\]. Moreover, *ZNF582* has been reported to exhibit a high methylation rate in cervical adenocarcinoma, which has been difficult to diagnose \[[@R28]\].

Here we report a case-control study of diagnosis of CIN3+ in hrHPV-positive cases negative for HPV 16/18 by detection of methylated DNA, HPV genotyping, liquid-based cytology, and combinations thereof. The results were analyzed following the recommended primary HPV screening protocol algorithm \[[@R13]\]. The analysis procedure was as follows: hrHPV-positive patients were triaged through genotyping for HPV16/18 and reflex tests for the 12 hrHPV genotypes (excluding HPV-16/18). The results of the reflex tests, including testing of the methylation status of *PAX1*, *ZNF582*, *SOX1*, and *NKX6-1* and liquid Pap smears, were compared and analyzed. We propose that this approach would be useful in outpatient departments of hospitals in highly populated countries, where screening is not readily accessible through community-based settings.

RESULTS {#s2}
=======

Characteristics of subjects and colposcopic biopsy results {#s2_1}
----------------------------------------------------------

In total, 461 patients were enrolled in this study, of which 12 were excluded, 137 were hrHPV-negative, and 312 were hrHPV positive (Figure [1](#F1){ref-type="fig"}). The overall sensitivity and specificity for identification of CIN3+ in hrHPV-positive patients were 98.10% and 46.05%, respectively. The percentage of HPV-16/18-positive hrHPV patients in each pathological category was as follows: normal (19.00%); CIN1 (27.77%); CIN2 (30.76%); CIN3 (50.70%); carcinoma in situ (CIS) (73.33%); and squamous cell carcinoma (SCC)/ adenocarcinoma (AC) (81.15%). The sensitivity of HPV16/18, *ZNF582*^*m*^, and *PAX1*^*m*^ */ZNF582*^*m*^ was 66.5%, 77.4% and 86.5% for CIN3+ lesions in the HPV positive patients (n=312), respectively. The specificity of HPV16/18, *ZNF582*^*m*^, and *PAX1*^*m*^ */ZNF582*^*m*^ was 77.1%, 77.7%, and 65.0%, respectively. The referral rate of HPV16/18, *ZNF582*^*m*^, and *PAX1*^*m*^ */ZNF582*^*m*^ was 44.6%, 50.0%, and 60.6%, respectively. There were 173 HPV-16/18-negative hrHPV patients, of whom 81 (46.82%) had normal pathologic results, 13 (7.51%) were CIN1, 27 (15.60%) CIN2, 35 (20.23%) CIN3, 4 (2.31%) CIS, and 13 (7.51%) SCC. The demographic characteristics, reflex testing results (including cytology), most common HPV genotypes in Chinese women, and methylation results for *PAX1*, *ZNF582*, *SOX1*, and *NKX6-1* are presented in Table [1](#T1){ref-type="table"} . In the cytology results for the hrHPV HPV 16/18-negative cohort, 149 (86.12%) subjects were classified at or above the atypical squamous cells of undetermined significance (ASC-US+) level, of which 93 were ASC-US, 6 LSIL, and 50 had higher grade lesions (ASC-H/AGC/HSIL+). The percentage of positive HPV genotypes determined by the reflex tests (alone or in combination with the non-16/18 types of hrHPV) was 32.37% for HPV-52, 26.59% for HPV-58, 10.40% for HPV-33, 8.09% for HPV-31, and 41.62% for HPV- 35/45/51/56/59/66/68. The positive rate for individual methylated genes in the CIN3+ group was 71.15%, 59.62%, 69.23%, and 59.62% for *PAX1*^*m*^, *ZNF582*^*m*^, *SOX1*^*m*^, and *NKX6-1*^*m*^, respectively.

![Study flow chart from enrollment to hrHPV outcome\
A total of 461 women participated in cervical cancer screening at the colposcopy examination room of the Department of Obstetrics & Gynecology, Xiangya Hospital. All women underwent colposcopy and biopsy. Histopathology diagnoses were used as endpoints for the analysis. Twelve women were excluded because they did not meet the inclusion criteria. CIN1, cervical intraepithelial neoplasia type 1; CIN2, cervical intraepithelial neoplasia type 2; CIN3, cervical intraepithelial neoplasia type 3; CIS, carcinoma in situ; SCC, squamous cell carcinoma; AC, adenocarcinoma.](oncotarget-08-62274-g001){#F1}

###### The distribution DNA methylated genes and HPV genotyping tests for a non-16/18 high risk type positive women

  Cutoff                                Histological results   Total                                                                                
  ------------------------------------- ---------------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------------
  **Number of subjects**                                                                                                                            
  N                                     81                     13               27               35               4                13               173
  \%                                    46.82%                 7.51%            15.61%           20.23%           2.31%            7.51%            100%
  Age                                                                                                                                               
  Mean ± SD                             41.9 ± 10.0            43.0 ± 10.8      37.2 ± 11.2      42.1± 6.9        45.0 ± 7.5       52.2 ± 9.5       42.1 ± 10.1
  (range)                               (25.5 to 77.8)         (29.0 to 65.2)   (21.8 to 61.2)   (28.7 to 62.5)   (36.7 to 64.2)   (38.2 to 70.5)   (21.8 to 77.8)
  **Cytology results**                                                                                                                              
  Normal                                22                     1                0                0                0                1                24
  \%                                    91.66%                 4.17%            0.00%            0.00%            0.00%            4.17%            100%
  ASC-US                                50                     8                22               12               0                1                93
  \%                                    53.76%                 8.60%            23.66%           12.90%           0.00%            1.08%            100%
  LSIL                                  1                      2                0                3                0                0                6
  \%                                    16.67%                 33.33%           0.00%            50.00%           0.00%            0.00%            100%
  ASC-H/AGC/HSIL+                       8                      2                5                20               4                11               50
  \%                                    61.54%                 15.38%           18.52%           57.14%           100.0%           84.62%           100%
  **Detection modality or test used**                                                                                                               
  HPV31                                 5                      0                2                4                0                3                14
  \%                                    6.17%                  0.00%            7.41%            11.43%           0.00%            23.08%           8.09%
  HPV33                                 4                      1                4                8                0                1                18
  \%                                    4.94%                  7.69%            14.81%           22.86%           0.00%            7.69%            10.40%
  HPV52                                 27                     3                9                14               0                3                56
  \%                                    33.33%                 23.08%           33.33%           40.00%           0.00%            23.08%           32.37%
  HPV58                                 20                     4                9                8                2                3                46
  \%                                    24.69%                 30.77%           33.33%           22.86%           50.00%           23.08%           26.59%
  HPV35/39/45/51/56/59/66/68            37                     6                12               11               2                4                72
  \%                                    45.68%                 46.15%           44.44%           31.43%           50.00%           30.77%           41.62%
  *PAX1*^*m*^ ΔCp≦9.0                   14                     2                8                23               4                10               61
  \%                                    17.28%                 15.38%           29.63%           65.71%           100.0%           76.92%           35.26%
  *ZNF582*^*m*^ ΔCp≦11.0                10                     3                3                14               4                13               47
  \%                                    12.35%                 23.08%           11.11%           40.00%           100.0%           100.0%           27.17%
  *SOX1*^*m*^ ΔCp≦8.0                   12                     5                4                21               4                11               57
  \%                                    14.81%                 38.46%           14.81%           60.00%           100.0%           84.62%           32.95%
  *NKX6.1*^*m*^ ΔCp≦11.0                27                     7                7                21               3                7                72
  \%                                    33.33%                 53.85%           25.93%           60.00%           75.00%           53.85%           41.62%

Sensitivity and specificity of testing for CIN3+ by analysis of methylated genes, HPV genotyping, and cytology {#s2_2}
--------------------------------------------------------------------------------------------------------------

The sensitivity, specificity, and AUC results for the different molecular reflex tests for detection of CIN3+ lesions, individually and in combination, are presented in Table [2](#T2){ref-type="table"} . Pap smears achieved 98.08% sensitivity and 19.01% specificity at the ASC-US cut-off value included in the interim clinical guidance. The AUC for HPV genotyping individually or combination was \< 60% and the odds ratio (OR) was \< 4. Three of the DNA methylation markers, i.e., *PAX1*^*m*^, *SOX1*^*m*^, and *ZNF582*^*m*^, used individually resulted in AUC \> 75%; *ZNF582*^*m*^had the highest AUC at 79.0% (confidence interval (CI), 71.2%--86.7%). The sensitivity and specificity of *ZNF582*^***m***^ in the identification of CIN3+ lesions were 76.92% and 80.99%, respectively.

###### The performance of PAX1^*m*^, ZNF582^*m*^, SOX1^*m*^, NKX6.1^*m*^ and HPV infection tests in detection of CIN3+ lesion

  Target genes                   Cutoff             Sensitivity (%) (95%CI)   Specificity (%) (95%CI)   PPV (%) (95%CI)       AUC (%) (95%CI)    Odds ratio (95%CI)   *P* value
  ------------------------------ ------------------ ------------------------- ------------------------- --------------------- ------------------ -------------------- -----------
  Pap smear                      ≧ASCUS             98.08 (89.88-99.66)       19.01 (13.01-26.91)       34.23 (26.66-42.44)   58.5 (49.8-67.3)   11.97 (1.57-91.18)   0.002\$
                                 ≧ASC-H/AGC/HSIL+   67.31 (53.76-78.48)       87.60 (80.55-92.34)       70.00 (55.39-82.14)   77.5 (69.1-85.8)   14.55 (6.59-32.14)   \<0.001
  *PAX1*^*m*^                    ≦9.0               71.15 (57.73-81.67)       80.17 (72.18-86.29)       60.66 (49.31-72.93)   75.7 (67.4-83.9)   9.97 (4.72-21.06)    \<0.001
  *ZNF582*^*m*^                  ≦11.0              59.62 (46.07-71.84)       86.78 (79.60-91.69)       65.96 (50.69-79.14)   73.2 (64.3-82.0)   9.69 (4.51-20.80)    \<0.001
  *SOX1*^*m*^                    ≦8.0               69.23 (55.73-80.09)       82.64 (74.92-88.36)       63.16 (49.34-75.55)   75.9 (67.6-84.3)   10.71 (5.04-22.77)   \<0.001
  *NKX6.1*^*m*^                  ≦11.0              59.62 (46.07-71.84)       66.12 (57.30-73.94)       43.06 (31.43-55.27)   62.9 (53.7-72.0)   2.88 (1.47-5.63)     0.002
  HPV31                                             13.46 (6.68-25.27)        94.21 (88.54-97.17)       50.00 (23.04-76.96)   53.8 (44.2-63.4)   2.53 (0.84-7.63)     0.090
  HPV33                                             17.31 (9.38-29.73)        92.56 (86.47-96.04)       50.00 (26.02-73.98)   54.9 (45.3-64.6)   2.61 (0.97-7.00)     0.051
  HPV52                                             32.69 (21.52-46.24)       67.77 (59.01-75.44)       30.36 (18.78-44.10)   50.2 (40.8-59.6)   1.02 (0.51-2.04)     0.953
  HPV58                                             25.00 (15.23-38.21)       72.73 (64.18-79.87)       29.79 (17.34-44.89)   48.9 (39.5-58.2)   0.89 (0.42-1.87)     0.756
  HPV31/33                                          30.77 (19.91-44.27)       88.43 (81.51-92.98)       53.33 (34.33-71.66)   59.6 (50.0-69.2)   3.40 (1.51-7.64)     0.002
  HPV52/58                                          57.69 (44.19-70.13)       40.50 (32.17-49.40)       29.41 (20.80-39.25)   49.1 (39.7-58.5)   0.93 (0.48-1.79)     0.824
  HPV31/33/52/58                                    84.62 (72.48-91.99)       29.75 (22.33-38.42)       34.11 (25.99-42.97)   57.2 (48.2-66.2)   2.33 (1.00-5.44)     0.047
  HPV35/39/45/51/56/59/66/68                        32.69 (21.52-46.24)       54.55 (45.67-63.14)       23.61 (14.40-36.09)   43.6 (34.4-52.8)   0.58 (0.30-1.15)     0.118
  *PAX1*^*m*^ or *ZNF582*^*m*^                      78.85 (65.97-87.76)       73.55 (65.06-80.60)       56.16 (44.05-67.76)   76.2 (68.3-84.1)   10.37 (4.76-22.58)   \<0.001
  *PAX1*^*m*^ or *SOX1*^*m*^                        80.77 (68.10-89.20)       74.38 (65.94-81.32)       57.53 (45.41-69.03)   77.6 (69.9-85.3)   12.19 (5.47-27.18)   \<0.001
  *PAX1*^*m*^ or *NKX6.1*^*m*^                      80.77 (68.10-89.20)       57.85 (48.94-66.28)       45.16 (34.81-55.83)   69.3 (61.0-77.6)   5.77 (2.65-12.56)    \<0.001
  *ZNF582*^*m*^ or *SOX1*^*m*^                      75.00 (61.79-84.77)       76.86 (68.59-83.48)       58.21 (45.52-70.15)   75.9 (67.8-84.0)   9.96 (4.68-21.24)    \<0.001
  *ZNF582*^m^ or *NKX6.1*^m^                        78.85 (65.97-87.76)       57.85 (48.94-66.28)       45.45 (35.41-55.77)   68.3 (59.9-76.8)   5.12 (2.4-10.91)     \<0.001
  *SOX1*^*m*^ or *NKX6.1*^*m*^                      82.69 (70.27-90.62)       60.33 (51.43-68.60)       47.25 (36.69-58.00)   71.5 (63.4-79.6)   7.27 (3.25-16.26)    \<0.001

*P* value determined by chi-square test or by Fisher's exact test; CI, confidence interval; HPV, human papillomavirus; hrHPV, high-risk human papillomavirus; odds ratio for CIN3+; *Gene*^*m*^, methylated *Gene*.

Dual DNA methylation testing of positivity for either gene in pairs of *PAX1*^*m*^/*ZNF582*^*m*^, *PAX1*^*m*^/*SOX1*^*m*^, and *ZNF582*^*m*^/*SOX1*^*m*^ resulted in AUC of 76.2%, 77.6%, and 75.9%. The highest odds ratios for combinations of two methylated genes were those for *PAX1*^*m*^/*ZNF582*^*m*^ and *PAX*1^m^/*SOX1*^*m*^, at 10.37 and 12.19, respectively.

Colposcopy referral rates: the rates of positivity for each test in the different histologic categories {#s2_3}
-------------------------------------------------------------------------------------------------------

A bar chart showing the percentage of women with cervical changes in different histologic categories who tested positive by Pap smear or combinations of HPV genotyping and gene methylation tests is presented in Figure [2](#F2){ref-type="fig"} (only the more effective genotype/methylation tests are presented). Analysis of the distribution of positive results for each histologic category demonstrated that Pap smears had very high positive rates in each category, HPV-31/33/52/58 genotype was associated with an 84.6% positive rate for CIN3+, in addition, with 70.2% positivity for CIN2-. The dual methylation markers *PAX1*^*m*^/*ZNF582*^*m*^, *PAX1*^*m*^/*SOX1*^*m*^, and *SOX1*^*m*^/*ZNF582*^*m*^ were the most discriminatory. *ZNF582*^*m*^ combined with either *PAX1*^*m*^ or *SOX1*^*m*^ achieved 100% positivity for histology results indicating cancer; however, the positive rate decreased to between 62.86% and 74.29% for the CIN3 category (Figure [2](#F2){ref-type="fig"}).

![The percentage of positive findings in the pathologic categories using different individual or combined tests\
The bar chart shows the positive rate for each test in each histologic category. CIN1, cervical intraepithelial neoplasia type 1; CIN2, cervical intraepithelial neoplasia type 2; CIN3, cervical intraepithelial neoplasia type 3; CIS, carcinoma in situ; SCC, squamous cell carcinoma; AC, adenocarcinoma.](oncotarget-08-62274-g002){#F2}

Colposcopy is a diagnostic procedure performed by physicians to examine the cervix, vagina, and vulva closely for signs of disease. Due to the high cost and insufficient availability of colposcopy, it is desirable to reduce the number of colposcopy referrals, while not missing women with severe dysplasia or carcinoma (CIN3, CIS, or SCC). Our results indicated that the referral rates for colposcopy after reflex tests using the individual methylated genes *PAX1*^*m*^, *ZNF582*^*m*^ and *SOX1*^*m*^ were 35.26%, 27.17%, and 32.95%, respectively, which was lower than the rate with cytology (86.1%; cut off at ASC-US) (Table [1](#T1){ref-type="table"}). Using dual tests for methylated genes (*PAX1*^*m*^/*SOX1*^*m*^ or *PAX1*^*m*^/*ZNF582*^*m*^) as reflex tests, the positive rates for CIN3+ histology were 6.94% higher than for *PAX1*^*m*^ alone, and use of the *SOX1*^*m*^/*ZNF582*^*m*^ dual test increased positive rates for CIN3+ by 11.56% compared with *ZNF582*^*m*^ alone, as shown in Figure [2](#F2){ref-type="fig"}.

DISCUSSION {#s3}
==========

HPV infection is a major cause of cervical cancer. HPV genotype testing, based on the identification of HPV DNA in the cervix, has the potential to improve HPV testing and demonstrates higher sensitivity for high-grade CIN than cytology testing, based on the identification of changes in cellular morphology. DNA testing for high-risk HPV types is frequently performed in parallel with cytology to detect high-grade dysplasia and cervical cancer, particularly in women over 30 years of age. HPV DNA testing is a relatively simple process and therefore advantageous for large-scale screening in China or developing countries, which are lacking cytology infrastructure and expert cytologists. In addition, HPV DNA testing of self-collected vaginal samples can be less uncomfortable for conservative women, and can increase participation rates in primary or routine screening for cervical cancer \[[@R29]--[@R32]\].

It is believed that only persistent HPV infections are associated with pre-cancerous lesions. Despite its high sensitivity, hrHPV testing cannot distinguish whether or not an HPV-positive result is associated with a clinically relevant lesion, and a positive hrHPV result may lead to over-interpretation of minor cellular abnormalities, thereby reducing the specificity of this technique \[[@R33]\]. Therefore, combination tests for methylated *PAX1*, *ZNF582*, and HPV16/18 that can distinguish between the CIN3+ and CIN2- groups are urgently required. Cytology is considered appropriate for application as a reflex test for hrHPV-positive women \[[@R34]\]. For detection of CIN3+, the sensitivity of triage testing by cytology alone was 65.8% (95% CI, 50.7--80.9) and the specificity was 78.6% (95% CI, 72.8--84.3) \[[@R35]\]. When using other technology for hrHPV triage, the sensitivity of p16/Ki-67 dual staining for ≥CIN3 was 93.8%, which did not differ significantly from the results obtained from Pap cytology (87.7%). The specificity of p16/Ki-67 dual staining for ≥CIN3 was 51.2%, whereas it was 44.9% for Pap cytology \[[@R36]\]. Recent studies have proposed methylation biomarkers as potential tools for triage of hrHPV-positive women \[[@R37]--[@R42]\].

There is increasing evidence that testing for methylated genes could replace cytology as a reflex test for women positive for the 12 hrHPV types other than HPV-16/18, and interim clinical guidance approves the use of such tests as an appropriate triage tool for hrHPV \[[@R13], [@R43]\]. We propose a cervical cancer screening strategy using the hrHPV genotyping assay and methylation analysis as triage tests (Figure [3](#F3){ref-type="fig"}). In hrHPV-positive patients, positive results in HPV-16/18 testing or gene methylation (*PAX1*^*m*^/*ZNF582*^*m*^) testing indicate a need for biopsy during colposcopy for diagnosis of CIN3+ lesions. We suggest a 1-year follow-up of patients with positivity for the 12 high-risk HPV genotypes but negative results for HPV-16/18 and methylated gene testing. Because HPV-16/18 and methylation co-testing demonstrated a 100% rate of positivity for cervical cancer identification in this study, we suggest that because of the lower risk for CIN3+ lesions, patients with negative results by hrHPV and methylated gene testing should be followed up after 5 years or more \[[@R39]\].

![Proposed cervical cancer screening strategy using the hrHPV assay as a primary screening tool and testing for HPV-16/18 and methylation of *PAX1*/*ZNF582* as reflex triage tests\
In this proposed scenario, the hrHPV DNA assay is used as the primary screening test, and women without hrHPV infection undergo follow-up 3 to 5 years later. Samples from women with hrHPV infection undergo analysis of *PAX1* or *ZNF582* methylation and women positive for HPV-16/18 are referred for colposcopy. Patients positive for hrHPV types other than HPV-16/18 undergo testing for *PAX1* or *ZNF582* methylation. Patients with positive results for one of the two methylated genes are referred for colposcopy. Additionally, women testing positive for hrHPV but negative for methylation may undergo repeat HPV genotyping and DNA methylation analysis after 1 year.](oncotarget-08-62274-g003){#F3}

Several previous studies have supported the great promise of analysis of *PAX1*^*m*^ and *ZNF582*^*m*^ for detection of high-grade CIN lesions and cervical cancer. We explored the value of triage testing of hrHPV-positive women by combined testing for positivity for HPV-16/18 or the dual methylated markers, *PAX1*^*m*^ or *ZNF582*^*m*^. Combined triage resulted in substantially higher sensitivity and specificity for CIN3+, compared with cytology alone, genotyping for the 12 other hrHPV types individually, or cytology with HPV-16/18 testing. The strengths of the present study lie in its use of a delinked case-control study design and the incorporation of all histological results, including those of the normal cytology group.

In 2012, the ACS proposed new screening guidelines that included using age-adjusted screening methodology as well as cytological and HPV co-testing. HPV-16/18 typing has been recommended for hrHPV-positive women \[[@R44]\]; however, geographic variation exists in the distribution of HPV genotypes. In Asia, in addition to HPV types 16 and 18, types 52 and 58 are frequently observed in patients with invasive cervical cancers \[[@R2], [@R45]-[@R47]\]. Adoption of hrHPV testing will result in many more women becoming aware of their HPV status; however, this could result in psychological trauma or unnecessary anxiety about cervical cancer. The top five hrHPV genotypes identified in infections in 37 cities in China were HPV-16 (35.0%), HPV-52 (32.3%), HPV-58 (21.2%), HPV-59 (17.5%), and HPV-39 (17.2%) \[[@R47]\]. The proportion of these HPV genotypes that was associated with cervical cancer was HPV-16/18 (69.7%), HPV-58 (7.2%), HPV-52 (3.6%), HPV-33 (3.6%), and HPV-31 (2.3%); for other hrHPV types, the rates of cervical cancer were \< 1% in a meta-analysis of data from Chinese women \[[@R3]\]. In the present study, the highest rates of cervical cancer were identified in women infected with hrHPV types HPV-16/18 (81%), HPV-58 (4.3%), HPV-52 (4.3%), HPV-31 (4.3%), and HPV-33 (1.4%), with other hrHPV types making up a further 4.3%. HPV types 52/58/31/33 made up 16.7% and 14.3% of cervical cancer diagnoses in the meta-analysis data and in our study, respectively. In the meta-analysis, HPV types 52/58/31/33 were detected in 48.0% of patients with LSIL and normal pathology, leading to an increase in false-positive rates when hrHPV testing was used as a triage tool.

The huge number of hrHPV patients referred for colposcopic examination and follow-up could be an extra burden in China, should HPV testing be used for hospital-based opportunistic screening. Our data demonstrate that following the current interim clinical guidance would not significantly reduce the referral rate for colposcopy. However, the substantial variability in sensitivity observed among areas with different cytology infrastructures and insufficient numbers of experienced cytologists are other factors reducing the referral rate for colposcopy in China. Comparison of cytology and dual methylated markers as reflex tests indicated that the dual methylated markers resulted in a referral rate for colposcopic examination that was 24.4% of the rate for cytology.

The present study has some potential limitations. Not all hrHPV-positive patients were referred for colposcopy examination because of the limited budget of the clinical study and based on the independent judgment of gynecologists in clinic. In addition, 144 hrHPV-ASC-US patient samples were collected during colposcopy because the majority of patients with obvious cervical cancer underwent biopsy immediately following abnormal Pap smear test results and clinical observation in the outpatient department. Other limitations include the small sample size and a lack of extensive and long-term follow-up information. In addition, the use of dual methylated markers as the only triage biomarker for hrHPV-positive women was not analyzed in this study, and this study is not representative of a typical screening population.

We recommend a new hrHPV flow-chart procedure for primary screening for cervical cancer. Our study suggests that the dual methylated markers, *PAX1*^*m*^ and *ZNF582*^*m*^, combined with HPV-16/18 testing, could help to reduce the number of hrHPV- positive women being referred for colposcopy. Furthermore, implementation of our recommendations could simplify the logistics of follow-up care, especially in regions where colposcopy is not readily available. We propose that the suggested approach would be useful in outpatient departments of hospitals in highly populated countries where screening is not readily accessible through community-based settings.

MATERIALS AND METHODS {#s4}
=====================

Patient recruitment {#s4_1}
-------------------

In accordance with the Declaration of Helsinki, all patients provided informed consent for their participation in the clinical study protocol approved by the Institutional Review Board of the Department of Clinical Pharmacology at Xiangya Hospital, Central South University, China. The clinical trial was registered in the Chinese Clinical Trial Registry (ChiCTR-DOD-14005446). Study inclusion criteria were females who were sexually active and not pregnant, had an intact uterus, and had no history of treatment for cervical intraepithelial neoplasia (CIN) or cervical cancer. Patients who had a history of cancer related to the reproductive tract, therapy for cervical lesions, HPV vaccinations, or a current pregnancy were excluded. The recruited subjects were in attendance following referral for colposcopy examination, and consisted of patients with both normal Pap and abnormal Pap smear results, inflammation symptoms, cervical erosion, bleeding symptoms, or suspected cervical cancer.

The sub-group of patients who were hrHPV-positive was invited to the colposcopic examination room of the Department of Obstetrics & Gynecology to participate in a blinded study where testers were not provided with clinical data. After patients signed the informed consent form, each underwent a colposcopic examination and biopsy. The cytology results were classified according to the 2001 Bethesda System (TBS 2001). Colposcopy-directed biopsies were performed for histological analysis, according to standard procedures in China. The final diagnosis was based on the results of tissue-proven pathology. Standard guidelines for the management and treatment of cervical neoplasia were followed in all patients \[[@R47]\]. All patient recruitment and clinical information collection processes were periodically monitored, and Good Clinical Practice (GCP) guidelines were followed.

In total, 461 patients were enrolled in the study from November 2011 to March 2013. Twelve patients were excluded based on the exclusion criteria, including five who were excluded because of poor-quality DNA specimens. This study focusses on data from the sub-group of 312 women who were hrHPV-positive following interim clinical guidance \[[@R13]\].

Specimen collection and DNA preparation {#s4_2}
---------------------------------------

All liquid-based cytology samples were clinician-collected using the Cytoprep Brush (Hospitex Diagnostics SRL, Sesto Fiorentino, Italy) and preserved in CytoFast Solution (Hospitex Diagnostics SRL, Sesto Fiorentino, Italy) in the clinic one week prior to the colposcopy visit. Residual cervical cells from cytological tests were used for HPV genotyping and methylation detection tests for the four genes. All specimens collected were given an identification number and delinked from patient clinical information until final data analysis. All molecular tests were performed at the Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, China, following Good Laboratory Practice (GLP) guidelines. The cells were centrifuged and stored in phosphate-buffered saline at -20°C from the day of collection. Genomic DNA (gDNA) was extracted from the collected cells using the QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany). A BioSpec-nano spectrophotometer (Shimadzu Corporation, Tokyo, Japan) was used to quantify the amount of extracted DNA.

DNA methylation tests {#s4_3}
---------------------

Briefly, 500 ng of gDNA was subject to bisulfite conversion using EZ DNA Methylation-Gold kits (Zymo Research, Irvine, CA, USA). The methylation levels of *PAX1*, *ZNF582*, *SOX1*, and *NKX6-1* were determined using the iStat Biomedical Q-PCR kit on the LightCycler LC480 real-time PCR system (Roche Applied Science, Penzberg, Germany), according to the manufacturer's protocol. The criteria for positive and negative results for the methylated genes were based on the delta crossing point (Cp) values, as determined in previous studies \[[@R20], [@R23], [@R25]\].

Laboratory methods for HPV DNA amplification and genotyping {#s4_4}
-----------------------------------------------------------

The hrHPV typing testing (EpiGene HPV-M SpeedGel Kit; iStat Biomedical Co., Ltd., Taiwan) was a clinical test performed using a nested multiplex PCR assay that combined degenerate E6/E7 consensus primers and type-specific primers as previously described \[[@R48], [@R49]\]. The hrHPV genotype was determined according to the size of the nested PCR amplification product.

Statistical analyses {#s4_5}
--------------------

The positive cutoff values for methylated genes were determined as *PAX1*^*m*^ = ΔCp ≤ 9, *SOX1*^*m*^ = ΔCp ≤ 8, *ZNF582*^*m*^ = ΔCp ≤ 11, and *NKX6-1*^*m*^ = ΔCp ≤ 11. SPSS software (version 16.0, Chicago, IL, USA) was used for all statistical analyses. Both Chi-squared and Fisher's exact tests were used to analyze the status of the methylated genes or of HPV genotyping in different combinations. Fisher's exact test is considered more accurate than the chi-squared test when the sample size is smaller than five. A cross-validated receiver operating characteristic (ROC) curve was generated and the area under the ROC curve (AUC) for CIN3+ lesions was calculated for each detection method. The sensitivity, specificity, and odds ratio (OR) with 95% confidence interval (CI) were calculated for lesions classified as CIN3 or worse. All tests were two-sided and differences were considered statistically significant at *P* \< 0.05.
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